Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

261. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. BACKGROUND: Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce the risk of cardiovascular events substantially. METHODS: In a trial with 2-by-2 factorial design, we randomly assigned 12,705 participants at intermediate risk who did not have cardiovascular disease to rosuvastatin (10 mg per day) or placebo (...) ), and hydrochlorothiazide (12.5 mg per day) was associated with a significantly lower rate of cardiovascular events than dual placebo among persons at intermediate risk who did not have cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; ClinicalTrials.gov number, NCT00468923 .).

NEJM2016 Full Text: Link to full Text with Trip Pro

262. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. BACKGROUND: Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without (...) cardiovascular disease. METHODS: In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants in 21 countries who did not have cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included revascularization, heart failure, and resuscitated

NEJM2016 Full Text: Link to full Text with Trip Pro

263. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. BACKGROUND: Antihypertensive therapy reduces the risk of cardiovascular events among high-risk persons and among those with a systolic blood pressure of 160 mm Hg or higher, but its role in persons at intermediate risk and with lower blood pressure is unclear. METHODS: In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants at intermediate risk who did not have cardiovascular (...) disease to receive either candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke; the second coprimary outcome additionally included resuscitated cardiac arrest, heart failure, and revascularization. The median follow-up was 5.6 years. RESULTS: The mean blood pressure of the participants at baseline was 138.1/81.9 mm Hg

NEJM2016 Full Text: Link to full Text with Trip Pro

264. Sexual counselling for sexual problems in patients with cardiovascular disease.

Sexual counselling for sexual problems in patients with cardiovascular disease. BACKGROUND: Sexual problems are common among people with cardiovascular disease. Although clinical guidelines recommend sexual counselling for patients and their partners, there is little evidence on its effectiveness. OBJECTIVES: To evaluate the effectiveness of sexual counselling interventions (in comparison to usual care) on sexuality-related outcomes in patients with cardiovascular disease and their partners (...) reported on satisfaction in how sexual issues were addressed in cardiac rehabilitation services. AUTHORS' CONCLUSIONS: We found no high quality evidence to support the effectiveness of sexual counselling for sexual problems in patients with cardiovascular disease. There is a clear need for robust, methodologically rigorous, adequately powered RCTs to test the effectiveness of sexual counselling interventions for people with cardiovascular disease and their partners.

Cochrane2016

265. Telehealth for Patients with Cardiovascular Disease: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines

Telehealth for Patients with Cardiovascular Disease: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines Telehealth for Patients with Cardiovascular Disease: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines | CADTH.ca Find the information you need Telehealth for Patients with Cardiovascular Disease: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines Telehealth for Patients with Cardiovascular Disease: A Review of the Clinical (...) -effectiveness of telemonitoring in patients with CAD requiring cardiac rehabilitation, but telehealth interventions do not have inferior outcomes compared to center-based supervised programs, and telephone support may reduce hospitalizations and reduce risk factors for heart disease. For patients with heart diseases requiring implantable cardiac devices, the costs of telemonitoring were lower than conventional hospital monitoring. Pacemaker telemonitoring led to earlier cardiovascular event detection

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016

266. Study progress of berberine for treating cardiovascular disease

Study progress of berberine for treating cardiovascular disease 29063012 2018 11 13 2095-882X 1 4 2015 Dec Chronic diseases and translational medicine Chronic Dis Transl Med Study progress of berberine for treating cardiovascular disease. 231-235 10.1016/j.cdtm.2015.11.006 Berberine (BBR) is a natural alkaloid isolated from the Coptis chinensis . While this plant has been used in Chinese medicine for more than 2500 years, interest in its effects in treating cardiovascular disease has been (...) . eng Journal Article Review 2016 01 12 China Chronic Dis Transl Med 101679934 2095-882X Berberine Cardiovascular disease Mechanism Progress 2015 04 21 2017 10 25 6 0 2016 1 12 0 0 2016 1 12 0 1 epublish 29063012 10.1016/j.cdtm.2015.11.006 S2095-882X(15)00072-9 PMC5643735 Drug Metab Dispos. 2004 Apr;32(4):405-12 15039293 Phytother Res. 2008 Aug;22(8):999-1012 18618524 Nat Med. 2004 Dec;10(12):1344-51 15531889 J Mol Cell Cardiol. 2009 Feb;46(2):234-40 19014947 Acta Pharmacol Sin. 2001 Feb;22(2):125

Chronic diseases and translational medicine2016 Full Text: Link to full Text with Trip Pro

267. Prevention of Cardiovascular Disease in Women

Prevention of Cardiovascular Disease in Women 2016 Prevention of Cardiovascular in women (2 nd edition) Disease 1 2016 STATEMENT OF INTENT This guideline was developed to be a guide for best clinical practice in the management of cardiovascular diseases in women, based on the best available evidence at the time of development. Specific attempts were made to use local data and publications to ensure local relevance. Adherence to this guideline does not necessarily lead to the best clinical (...) Available on the following websites: http://www.moh.gov.my http://www.acadmed.org.my This is an update to the Clinical Practice Guidelines on Prevention of Heart Disease in Women published in 2008. This CPG supersedes the previous CPG.FOREWORD BY THE DIRECTOR-GENERAL OF THE MINISTRY OF HEALTH MALAYSIA 2 2016 Datuk Dr Noor Hisham Abdullah Director-General of Health Malaysia Cardiovascular disease, till this day, remains the primary cause of mortality globally. Although it affects both genders, a greater

Ministry of Health, Malaysia2016

268. Exemplar clinical pathways for a stratified approach to cardiovascular disease

Exemplar clinical pathways for a stratified approach to cardiovascular disease Exemplar clinical pathways for a stratified approach to cardiovascular disease Summary report of a meeting held on 17 March 2016 by the Academy of Medical Sciences, and supported by NHS England. Disclaimer This document reflects the views of participants expressed at the meeting and does not necessarily represent the views of all participants or of the Academy of Medical Sciences or NHS England. For further (...) to cardiovascular disease’. This meeting aimed to build upon the findings of the previous roundtable centred on the adoption of stratification in diabetes, and to discuss different aspects of the clinical pathways for cardiovascular disease including commissioning, awareness, education and training, and health economics. The meeting brought together participants from across the healthcare sector to consider the drivers for adoption of a stratified approach, barriers to implementation and next steps

Academy of Medical Sciences2016

269. Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling

Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: best marker for monitoring and cost-effectiveness of different monitoring frequencies Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page (...) you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} The study found that regular lipid monitoring in individuals with and without cardiovascular disease is likely to be beneficial to both patients and to the health service, and frequent monitoring strategies appear to be cost-effective. {{author}} {{($index

NIHR HTA programme2016

270. Prevention and Management of Cardiovascular Disease Risk in Primary Care

Prevention and Management of Cardiovascular Disease Risk in Primary Care PREVENTION AND MANAGEMENT OF CARDIOVASCULAR DISEASE RISK IN PRIMARY CARE Clinical Practice Guideline | February 2015 These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making. OBJECTIVE Alberta primary care clinicians and their teams offer (...) primary and secondary prevention for cardiovascular disease (CVD) focused on CVD risk estimation and lipid management. TARGET POPULATION Men aged 40-75 Women aged 50-75 (optional start at age 40 for simplicity) EXCLUSIONS Men and women of any age with previously diagnosed familial hypercholesterolemia RECOMMENDATIONS ? Screen for CVD risk beginning at age 40 for men and 50 for women. PRACTICE POINT Always use a risk calculator with every lipid measurement to assess CVD risk. X Fasting for lipid tests

Toward Optimized Practice2016

271. Cohort study: Physical activity reduces cardiovascular disease risk in older adults

Cohort study: Physical activity reduces cardiovascular disease risk in older adults Physical activity reduces cardiovascular disease risk in older adults | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Physical activity reduces cardiovascular disease risk in older adults Article Text Aetiology/Harm Cohort study Physical activity reduces cardiovascular disease risk in older adults Simon Endes Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Soares-Miranda L , Siscovick DS , Psaty BM , et al . Physical

Evidence-Based Medicine (Requires free registration)2016

272. Randomised controlled trial: In hypertensive patients with elevated risk of cardiovascular disease, targeting systolic blood pressure to less than 120?mm?Hg significantly reduces the rate of fatal and non-fatal cardiovascular events as well as death from

Randomised controlled trial: In hypertensive patients with elevated risk of cardiovascular disease, targeting systolic blood pressure to less than 120?mm?Hg significantly reduces the rate of fatal and non-fatal cardiovascular events as well as death from In hypertensive patients with elevated risk of cardiovascular disease, targeting systolic blood pressure to less than 120 mm Hg significantly reduces the rate of fatal and non-fatal cardiovascular events as well as death from any cause (...) patients with elevated risk of cardiovascular disease, targeting systolic blood pressure to less than 120 mm Hg significantly reduces the rate of fatal and non-fatal cardiovascular events as well as death from any cause Article Text Therapeutics/Prevention Randomised controlled trial In hypertensive patients with elevated risk of cardiovascular disease, targeting systolic blood pressure to less than 120 mm Hg significantly reduces the rate of fatal and non-fatal cardiovascular events as well as death

Evidence-Based Medicine (Requires free registration)2016

273. Concern for Myocardial Infarction Risk Associated with Proton Pump Inhibitor Use in Patients With No Underlying Cardiovascular Disease

Concern for Myocardial Infarction Risk Associated with Proton Pump Inhibitor Use in Patients With No Underlying Cardiovascular Disease "Concern for Myocardial Infarction Risk Associated with Proton Pump Inh" by Natasha K. Ludwig < > > > > > Title Author Date of Award Fall 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Saje Davis-Risen, PA-C, MS Second Advisor Annjanette Sommers, PA-C, MS Rights . Abstract Background (...) of this review is to explore if PPI use is associated with an increased MI risk in patients with no underlying cardiovascular disease. Methods: An exhausted search of available medical literature was performed using MEDLINE-Ovid, MEDLINE-Pubmed, Web of Science, and CINAHL using the keywords proton pump inhibitors, myocardial infarction, and epidemiology. Relevant articles were assessed for validity using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Results: Four

Pacific University EBM Capstone Project2016

274. Systematic review with meta analysis: Observational studies are compatible with an association between saturated and trans fats and cardiovascular disease

Systematic review with meta analysis: Observational studies are compatible with an association between saturated and trans fats and cardiovascular disease Observational studies are compatible with an association between saturated and trans fats and cardiovascular disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Observational studies are compatible with an association between saturated and trans fats and cardiovascular disease Article Text Aetiology/Harm Systematic review with meta analysis Observational studies are compatible

Evidence-Based Medicine (Requires free registration)2016

275. Randomised controlled trial: In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates

Randomised controlled trial: In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use (...) of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus

Evidence-Based Medicine (Requires free registration)2016

276. Systematic review with meta analysis: Aspirin reduces cardiovascular events in primary prevention of cardiovascular disease but at a near equivalent risk of increased bleeding

Systematic review with meta analysis: Aspirin reduces cardiovascular events in primary prevention of cardiovascular disease but at a near equivalent risk of increased bleeding Aspirin reduces cardiovascular events in primary prevention of cardiovascular disease but at a near equivalent risk of increased bleeding | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin reduces cardiovascular events in primary prevention of cardiovascular disease but at a near equivalent risk of increased bleeding Article Text Therapeutics/Prevention Systematic review

Evidence-Based Medicine (Requires free registration)2016

277. Hearts: technical package for cardiovascular disease management in primary health care

Hearts: technical package for cardiovascular disease management in primary health care WHO IRIS: Hearts: technical package for cardiovascular disease management in primary health care Browse Related links Files in This Item: File Description Size Format 2.35 MB Adobe PDF Title: Hearts: technical package for cardiovascular disease management in primary health care Authors: Issue Date: 2016 Publisher: World Health Organization Place of publication: Geneva Language: English Description: 73 p

WHO2016

278. Nutrigenomics, the Microbiome, and Gene-Environment Interactions: New Directions in Cardiovascular Disease Research, Prevention, and Treatment

Nutrigenomics, the Microbiome, and Gene-Environment Interactions: New Directions in Cardiovascular Disease Research, Prevention, and Treatment Nutrigenomics, the Microbiome, and Gene-Environment Interactions: New Directions in Cardiovascular Disease Research, Prevention, and Treatment | Circulation: Genomic and Precision Medicine Search for this keyword Search Search for this keyword Search Header Publisher Menu AHA Scientific Statement Nutrigenomics, the Microbiome, and Gene-Environment (...) Interactions: New Directions in Cardiovascular Disease Research, Prevention, and Treatment A Scientific Statement From the American Heart Association Jane F. Ferguson , Hooman Allayee , Robert E. Gerszten , Folami Ideraabdullah , Penny M. Kris-Etherton , José M. Ordovás , Eric B. Rimm , Thomas J. Wang , Brian J. Bennett and on behalf of the American Heart Association Council on Functional Genomics and Translational Biology, Council on Epidemiology and Prevention, and Stroke Council https://doi.org/10.1161

American Heart Association2016

279. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication Final Update Summary: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 3/6/2018 4:20:40 PM You are here: Final Summary Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication Release Date: November 2016 (...) Recommendation Summary Population Recommendation Grade Adults aged 40 to 75 years with no history of CVD, 1 or more CVD risk factors, and a calculated 10-year CVD event risk of 10% or greater The USPSTF recommends that adults without a history of cardiovascular disease (CVD) (ie, symptomatic coronary artery disease or ischemic stroke) use a low- to moderate-dose statin for the prevention of CVD events and mortality when all of the following criteria are met: 1) they are aged 40 to 75 years; 2) they have 1

U.S. Preventive Services Task Force2016

280. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication

Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication Final Update Summary: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 3/6/2018 4:20:40 PM You are here: Final Summary Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication Release Date: April 2016 Recommendation Summary (...) Population Recommendation Grade Adults aged 50 to 59 years with a ≥10% 10-year CVD risk The USPSTF recommends initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years. Adults aged 60 to 69 years with a ≥10% 10-year CVD

U.S. Preventive Services Task Force2016